# Alopexx, Inc. — capital_raise/public_offering [completed]
Source: sec.gov · situation sit_0da0e50f6165153d3e04 · public 4040184565712388830 · retrieved 2026-08-19T12:01:55.949Z

## Overview
Alopexx, Inc. is a clinical-stage biotechnology company developing novel immune therapeutics, including vaccine AV0328 and monoclonal antibody F598, targeting poly N-acetyl glucosamine (PNAG) for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections.

Alopexx, Inc., a clinical-stage biotechnology company developing immune therapeutics targeting poly N-acetyl glucosamine (PNAG) for bacterial, fungal, and parasitic infections, is conducting a firm commitment initial public offering of 3,000,000 shares of common stock at an estimated price range of $10.00 to $12.00 per share. The company has applied for listing on NYSE American under the symbol "ALPX" and expects to satisfy listing requirements upon completion of the offering. Based on an assumed midpoint price of $11.00 per share, the company estimates net proceeds of approximately $30.1 million (or $34.7 million if underwriters exercise their 450,000-share over-allotment option in full), after deducting underwriting discounts and commissions and estimated offering expenses.

## Terms
- Counterparty: ThinkEquity · Consideration: cash · Price/share: $11

## Key dates
- Completed 2026-08-14

## Timeline
- 2026-08-14 · S-1/A (0001213900-26-090319): S-1/A - Alopexx, Inc. — *Alopexx, Inc. is a clinical-stage biotechnology company developing novel immune therapeutics, including vaccine AV0328 and monoclonal antibody F598, targeting poly N-acetyl glucosamine (PNAG) for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections.* Alopexx, Inc., a clinical-stage biotechnology company developing immune therapeutics targeting poly N-acetyl glucosamine (PNAG) for bacterial, fungal, and parasitic infections, is conducting a firm commitment initial public offering of 3,000,000 shares of common stock at an estimated price range of $10.00 to $12.00 per share. The company has applied for listing on NYSE American under the symbol "ALPX" and expects to satisfy listing requirements upon completion of the offering. Based on an assumed midpoint price of $11.00 per share, the company estimates net proceeds of approximately $30.1 million (or $34.7 million if underwriters exercise their 450,000-share over-allotment option in full), after deducting underwriting discounts and commissions and estimated offering expenses.
  https://www.sec.gov/Archives/edgar/data/1880995/0001213900-26-090319.txt

## Citations
- 0001213900-26-090319 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000121390026090319